Structured evidence table for Vitamin D Immune Support Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Vitamin D Immune Support Randomized Trial | Studies on vitamin D have increased tremendously since the vitamin D receptor VDR has been identified in the whole immune cell population, including macrophages, dendritic cells (DCs), T cells, and B cells []. | 3 | Shende Sandesh (2026) | Vitamin D as an Immuno-Endocrine Modulator: Discovering Its Role in Autoimmune Disorders and Host Defense Mechanisms |
| Vitamin D Immune Support Randomized Trial | 11 2 12 13 14 Vitamin D was historically confined to skeletal biology, primarily associated with calcium–phosphate homeostasis and the prevention of rickets, osteomalacia, and osteoporosis []. | 3 | Shende Sandesh (2026) | Vitamin D as an Immuno-Endocrine Modulator: Discovering Its Role in Autoimmune Disorders and Host Defense Mechanisms |
| Vitamin D Immune Support Randomized Trial | Accumulating evidence indicates that hypovitaminosis D is common in autoimmune disorders such as multiple sclerosis (MS), type 1 diabetes mellitus (T1DM), rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE), as well as in infectious diseases, including tuberculosis and acute respiratory tract infections []. | 3 | Shende Sandesh (2026) | Vitamin D as an Immuno-Endocrine Modulator: Discovering Its Role in Autoimmune Disorders and Host Defense Mechanisms |
| Vitamin D Immune Support Randomized Trial | 1 2 3 4 5 6 7 8 9 10 2 3 Vitamin D was historically confined to skeletal biology. | 3 | Shende Sandesh (2026) | Vitamin D as an Immuno-Endocrine Modulator: Discovering Its Role in Autoimmune Disorders and Host Defense Mechanisms |
| Vitamin D Immune Support Randomized Trial | Despite advances in screening, surgery, and targeted therapies, manycarriers still develop cancer, underscoring the importance of identifying any modifiable risk factors [,]. | 4 | Robaczyńska Joanna (2026) | The Potential Role of Vitamin D in BRCA1 Pathogenic Variant Carriers: A Narrative Review |
| Vitamin D Immune Support Randomized Trial | 5 6 6 7 BRCA1 Vitamin D has been proposed as a potential candidate; however, the available evidence remains limited and inconclusive. | 4 | Robaczyńska Joanna (2026) | The Potential Role of Vitamin D in BRCA1 Pathogenic Variant Carriers: A Narrative Review |
| Vitamin D Immune Support Randomized Trial | 8 9 10 11 12 13 BRCA1 BRCA1 BRCA1 BRCA1 BRCA1 Circulating vitamin D levels are modifiable through diet, supplementation, and sun exposure, making vitamin D status an attractive candidate as a potential risk modifier []. | 4 | Robaczyńska Joanna (2026) | The Potential Role of Vitamin D in BRCA1 Pathogenic Variant Carriers: A Narrative Review |
Source documents